2019
DOI: 10.1016/j.jchf.2018.10.010
|View full text |Cite
|
Sign up to set email alerts
|

Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

13
182
7
6

Year Published

2019
2019
2022
2022

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 145 publications
(208 citation statements)
references
References 30 publications
13
182
7
6
Order By: Relevance
“…Approximately 25% of all Dutch HF patients are in NYHA class III based on the latest CHECK HF registry findings [3]. Contemporary treatment of chronic HF shows a reasonably high adherence to European guidelines for the recommended drugs, when compared to US data in the CHAMP-HF registry [4,5]. Still, both registries show considerable room for improvement in HF therapy considering target or optimal dosing of medication [4,5].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Approximately 25% of all Dutch HF patients are in NYHA class III based on the latest CHECK HF registry findings [3]. Contemporary treatment of chronic HF shows a reasonably high adherence to European guidelines for the recommended drugs, when compared to US data in the CHAMP-HF registry [4,5]. Still, both registries show considerable room for improvement in HF therapy considering target or optimal dosing of medication [4,5].…”
Section: Introductionmentioning
confidence: 99%
“…Contemporary treatment of chronic HF shows a reasonably high adherence to European guidelines for the recommended drugs, when compared to US data in the CHAMP-HF registry [4,5]. Still, both registries show considerable room for improvement in HF therapy considering target or optimal dosing of medication [4,5]. So clearly, despite optimal medical treatment, there is a considerable residual risk, especially for patients in NYHA class III.…”
Section: Introductionmentioning
confidence: 99%
“…Besides the Fig. 4 Differences between the United States and the Netherlands in the use of (a) and dosing of (b) guidelinerecommended medication in patients with heart failure and reduced ejection fraction in the CHAMP-HF [43] and CHECK-HF [44] registries. MRA mineralocorticoid receptor antagonist (Adapted from [43,44], with permission) alleged benefit of spironolactone in the United States (US) and European participants of the TOPCAT trial [42] with spironolactone, this is the first evidence of a treatment or tool to improve the outcome in HFpEF patients.…”
Section: Cardiomems and Evidence In Hfpef Patientsmentioning
confidence: 99%
“…Several large cohorts and trials have reported dose, including a Swedish multicentre cohort (n = 2093) 33 ; the BIOSTAT-CHF Optimal dosing of medication in acute heart failure study (n = 2100) 16 ; the ESC-HF, 6 CHAMP-HF, 8 CHECK-HF, 31 and PINNACLE (n = 1421) 34 registries; and the GUIDE-IT trial. 35 The proportions prescribed ≥50% and target dose for each class are ACE-I/ARB 40% to 76% for ≥50% and 14% to 44% target; beta-blockers 31% to 55% for ≥50% and 6% to 28% target; and MRA 49% to 98% for ≥50% and 31% to 77% target.…”
Section: Target Dosingmentioning
confidence: 99%
“…In Danish, Dutch, or multinational registries that restricted analyses to HFrEF outpatients such as the Hjerteplus (n = 8792), 29 QUALIFY (n = 7092), 30 ESC-HF (n = 4792), 6 CHAMP-HF (n = 3518), 8 and CHECK-HF registries (n = 5701), 31 prescription rates ranged from 85% to 94% for ACE-I/ARBs, 81% to 93% for beta-blockers, and 32% to 69% for MRAs. This suggests slightly lower rates of ACE-I/ARB and MRA prescription in our cohort compared with ambulatory HFrEF patients, which can be explained in part by higher rates of renal dysfunction at baseline among hospitalized HF patients.…”
Section: Overall Prescription Ratesmentioning
confidence: 99%